{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:06:48Z","timestamp":1792699608103,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clinthera.2020.02.006","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T08:55:30Z","timestamp":1584089730000},"page":"614-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote"],"prefix":"10.1016","volume":"42","author":[{"given":"Xia","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuoer","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaicheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuguang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.02.006_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/ACO.0000000000000652","article-title":"Drug selection for ambulatory procedural sedation","volume":"31","author":"Barends","year":"2018","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.clinthera.2020.02.006_bib2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/phar.1806","article-title":"Remimazolam: pharmacologic considerations and clinical role in anesthesiology","volume":"36","author":"Wesolowski","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2020.02.006_bib3","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/ACO.0000000000000316","article-title":"Update on pharmacological management of procedural sedation for children","volume":"29","author":"Roback","year":"2016","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.clinthera.2020.02.006_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2125.1990.tb03755.x","article-title":"Pharmacokinetics of propofol when given by intravenous infusion","volume":"30","author":"Morgan","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.02.006_bib5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40272-017-0241-5","article-title":"Pharmacologic considerations for pediatric sedation and anesthesia outside the operating room: a review for anesthesia and non-anesthesia providers","volume":"19","author":"Khurmi","year":"2017","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.clinthera.2020.02.006_bib6","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1213\/ANE.0b013e3182a705ae","article-title":"A\u00a0phase Ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy","volume":"117","author":"Worthington","year":"2013","journal-title":"Anesth Analg"},{"key":"10.1016\/j.clinthera.2020.02.006_bib7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1213\/ANE.0000000000000548","article-title":"A\u00a0Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy","volume":"120","author":"Borkett","year":"2015","journal-title":"Anesth Analg"},{"key":"10.1016\/j.clinthera.2020.02.006_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.chest.2018.09.015","article-title":"Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy","volume":"155","author":"Pastis","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2020.02.006_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1213\/ANE.0b013e31823f0c28","article-title":"A\u00a0placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I. Safety, efficacy, and basic pharmacokinetics","volume":"115","author":"Antonik","year":"2012","journal-title":"Anesth Analg"},{"key":"10.1016\/j.clinthera.2020.02.006_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1213\/ANE.0b013e318241f68a","article-title":"A\u00a0placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part II. Population pharmacokinetic and pharmacodynamic modeling and simulation","volume":"115","author":"Wiltshire","year":"2012","journal-title":"Anesth Analg"},{"key":"10.1016\/j.clinthera.2020.02.006_bib11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3389\/fphar.2018.01316","article-title":"Population pharmacokinetic\/pharmacodynamic model-guided dosing optimization of a novel sedative HR7056 in Chinese healthy subjects","volume":"9","author":"Zhou","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2020.02.006_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchromb.2014.11.022","article-title":"Simultaneous determination of remimazolam and its carboxylic acid metabolite in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry","volume":"976\u2013977","author":"Zhou","year":"2015","journal-title":"J\u00a0Chromatogr B Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2020.02.006_bib13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1067\/mge.2000.107284","article-title":"Bispectral index monitoring of sedation during endoscopy","volume":"52","author":"Bower","year":"2000","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.clinthera.2020.02.006_bib14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.gie.2008.02.011","article-title":"An assessment of computer-assisted personalized sedation: a sedation delivery system to administer propofol for gastrointestinal endoscopy","volume":"68","author":"Pambianco","year":"2008","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.clinthera.2020.02.006_bib15","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/bcp.12413","article-title":"The central nervous system effects of the partial GABA-A\u03b12,3-selective receptor modulator AZD7325 in comparison with lorazepam in healthy males","volume":"78","author":"Chen","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.02.006_bib16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41401-018-0185-5","article-title":"Human pharmacology of positive GABA-A Subtype-selective receptor modulators for the treatment of anxiety","volume":"40","author":"Chen","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clinthera.2020.02.006_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0269881115620435","article-title":"NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects","volume":"30","author":"Zuiker","year":"2016","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.clinthera.2020.02.006_bib18","article-title":"An overview of the CNS-pharmacodynamic profiles of non-selective and selective GABA receptor modulators","volume":"2012","author":"Chen","year":"2012","journal-title":"Adv Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2020.02.006_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JCP.0000000000000251","article-title":"AZD6280, a novel partial \u03b3-aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers","volume":"35","author":"Chen","year":"2015","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2020.02.006_bib20","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/bcp.13204","article-title":"Pharmacodynamic response profiles of anxiolytic and sedative drugs","volume":"83","author":"Chen","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.02.006_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0269881108092595","article-title":"The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABAA 2,3 selective receptor modulator, in comparison with lorazepam in healthy volunteers","volume":"23","author":"de Haas","year":"2009","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.clinthera.2020.02.006_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.anclin.2017.01.017","article-title":"New hypnotic drug development and pharmacologic considerations for clinical anesthesia","volume":"35","author":"Tanious","year":"2017","journal-title":"Anesthesiol Clin"},{"key":"10.1016\/j.clinthera.2020.02.006_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/ALN.0b013e3181ae8460","article-title":"Is anesthesiology going soft?: trends in fragile pharmacology","volume":"111","author":"Egan","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1016\/j.clinthera.2020.02.006_bib24","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0024-3205(98)00411-1","article-title":"Cardiac effects of benzodiazepine receptor agonists and antagonists in the isolated rat heart: a comparative study","volume":"63","author":"Zeegers","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2020.02.006_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0006-3223(98)00295-9","article-title":"Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder","volume":"45","author":"Str\u00f6hle","year":"1999","journal-title":"Biol Psychiatr"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820301089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820301089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:22Z","timestamp":1758963142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820301089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0149291820301089"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.02.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}